Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus

Diabetes mellitus, a frequent metabolic complication in liver transplant recipients, may be produced by the diabetogenic effect of calcineurin inhibitors cyclosporine and tacrolimus. The aim of this study was to investigate the safety and metabolic effects of a gradual switch from cyclosporine or ta...

Full description

Bibliographic Details
Authors: Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d, Quiroga, J. (Jorge)|||/items/580a0a4e-16a6-446c-840c-3e225592fa4b, Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49, Pardo, F. (Fernando)|||/items/f4488eb3-3bf9-4dff-9d3f-402f36a1721e, Rotellar-Sastre, F. (Fernando)|||/items/833cb788-f4b9-404d-a18b-ae1c84369b51, Álvarez-Cienfuegos, J. (Javier)|||/items/88871d37-0dae-4312-a6d8-0596bc69158c, Prieto, J. (Jesús)|||/items/0d9c3dec-4a09-400d-8c83-23ece1096c71
Format: article
Publication Date:2003
Country:España
Institution:Universidad de Navarra
Repository:Dadun. Depósito Académico Digital de la Universidad de Navarra
Language:English
OAI Identifier:oai:dadun.unav.edu:10171/23180
Online Access:https://hdl.handle.net/10171/23180
Access Level:Open access
Keyword:Cyclosporine/adverse effects/therapeutic use
Diabetes Mellitus/blood/immunology
Graft Rejection/drug therapy/epidemiology
id ES_c607e7115f34c6c73ed2c2efaa7a2f80
oai_identifier_str oai:dadun.unav.edu:10171/23180
network_acronym_str ES
network_name_str España
repository_id_str
spelling Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes MellitusHerrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1dQuiroga, J. (Jorge)|||/items/580a0a4e-16a6-446c-840c-3e225592fa4bSangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49Pardo, F. (Fernando)|||/items/f4488eb3-3bf9-4dff-9d3f-402f36a1721eRotellar-Sastre, F. (Fernando)|||/items/833cb788-f4b9-404d-a18b-ae1c84369b51Álvarez-Cienfuegos, J. (Javier)|||/items/88871d37-0dae-4312-a6d8-0596bc69158cPrieto, J. (Jesús)|||/items/0d9c3dec-4a09-400d-8c83-23ece1096c71Cyclosporine/adverse effects/therapeutic useDiabetes Mellitus/blood/immunologyGraft Rejection/drug therapy/epidemiologyDiabetes mellitus, a frequent metabolic complication in liver transplant recipients, may be produced by the diabetogenic effect of calcineurin inhibitors cyclosporine and tacrolimus. The aim of this study was to investigate the safety and metabolic effects of a gradual switch from cyclosporine or tacrolimus to mycophenolate mofetil among 12 diabetic liver transplant recipients. One patient was withdrawn from the study due to gastrointestinal side effects. Of the 11 remaining patients, cyclosporine or tacrolimus was completely withdrawn in five patients. Two patients developed suspected acute rejection episodes that were controlled by increasing the tacrolimus dosage. Glycosylated hemoglobin A1C and C-peptide levels were significantly lower at 3 and 6 months after the initiation of mycophenolate mofetil (P<.03 in all cases). Furthermore, urea and uric acid levels were significantly reduced after the change of treatment. In conclusion, a switch from cyclosporine/tacrolimus to mycophenolate mofetil may produce beneficial metabolic effects in diabetic liver transplant recipients, but poses a risk of graft rejection.ElsevierDadun. Depósito Académico Digital Universidad de Navarra20122012-09-2520032003-01-0120032003-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/23180reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/231802026-06-21T12:47:57Z
dc.title.none.fl_str_mv Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
title Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
spellingShingle Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
Cyclosporine/adverse effects/therapeutic use
Diabetes Mellitus/blood/immunology
Graft Rejection/drug therapy/epidemiology
title_short Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
title_full Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
title_fullStr Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
title_full_unstemmed Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
title_sort Conversion From Calcineurin Inhibitors to Mycophenolate Mofetil in Liver Transplant Recipients With Diabetes Mellitus
dc.creator.none.fl_str_mv Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
Quiroga, J. (Jorge)|||/items/580a0a4e-16a6-446c-840c-3e225592fa4b
Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49
Pardo, F. (Fernando)|||/items/f4488eb3-3bf9-4dff-9d3f-402f36a1721e
Rotellar-Sastre, F. (Fernando)|||/items/833cb788-f4b9-404d-a18b-ae1c84369b51
Álvarez-Cienfuegos, J. (Javier)|||/items/88871d37-0dae-4312-a6d8-0596bc69158c
Prieto, J. (Jesús)|||/items/0d9c3dec-4a09-400d-8c83-23ece1096c71
author Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
author_facet Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
Quiroga, J. (Jorge)|||/items/580a0a4e-16a6-446c-840c-3e225592fa4b
Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49
Pardo, F. (Fernando)|||/items/f4488eb3-3bf9-4dff-9d3f-402f36a1721e
Rotellar-Sastre, F. (Fernando)|||/items/833cb788-f4b9-404d-a18b-ae1c84369b51
Álvarez-Cienfuegos, J. (Javier)|||/items/88871d37-0dae-4312-a6d8-0596bc69158c
Prieto, J. (Jesús)|||/items/0d9c3dec-4a09-400d-8c83-23ece1096c71
author_role author
author2 Quiroga, J. (Jorge)|||/items/580a0a4e-16a6-446c-840c-3e225592fa4b
Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49
Pardo, F. (Fernando)|||/items/f4488eb3-3bf9-4dff-9d3f-402f36a1721e
Rotellar-Sastre, F. (Fernando)|||/items/833cb788-f4b9-404d-a18b-ae1c84369b51
Álvarez-Cienfuegos, J. (Javier)|||/items/88871d37-0dae-4312-a6d8-0596bc69158c
Prieto, J. (Jesús)|||/items/0d9c3dec-4a09-400d-8c83-23ece1096c71
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Cyclosporine/adverse effects/therapeutic use
Diabetes Mellitus/blood/immunology
Graft Rejection/drug therapy/epidemiology
topic Cyclosporine/adverse effects/therapeutic use
Diabetes Mellitus/blood/immunology
Graft Rejection/drug therapy/epidemiology
description Diabetes mellitus, a frequent metabolic complication in liver transplant recipients, may be produced by the diabetogenic effect of calcineurin inhibitors cyclosporine and tacrolimus. The aim of this study was to investigate the safety and metabolic effects of a gradual switch from cyclosporine or tacrolimus to mycophenolate mofetil among 12 diabetic liver transplant recipients. One patient was withdrawn from the study due to gastrointestinal side effects. Of the 11 remaining patients, cyclosporine or tacrolimus was completely withdrawn in five patients. Two patients developed suspected acute rejection episodes that were controlled by increasing the tacrolimus dosage. Glycosylated hemoglobin A1C and C-peptide levels were significantly lower at 3 and 6 months after the initiation of mycophenolate mofetil (P<.03 in all cases). Furthermore, urea and uric acid levels were significantly reduced after the change of treatment. In conclusion, a switch from cyclosporine/tacrolimus to mycophenolate mofetil may produce beneficial metabolic effects in diabetic liver transplant recipients, but poses a risk of graft rejection.
publishDate 2003
dc.date.none.fl_str_mv 2003
2003-01-01
2003
2003-01-01
2012
2012-09-25
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/23180
url https://hdl.handle.net/10171/23180
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419038828920832
score 15,300719

Similar Items